Search results
Results from the WOW.Com Content Network
Genentech, Inc. is an American biotechnology corporation headquartered in South San Francisco, California, wholly owned by the Swiss multinational pharmaceutical company, the Roche Group. It became an independent subsidiary of Roche in 2009.
Genentech previously said the use of the drug in the indication accounts for a fraction of its overall revenue. The U.S. Food and Drug Administration had granted accelerated approval to Gavreto in ...
About Genentech. Founded more than 30 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or ...
Genentech had been able to manufacture, receive federal approval for, and market its own product, marking the successful execution of Swanson's plan to form out of Genentech a self sustainable biotech firm. [5] [6] [8] Swanson left his position as CEO in 1990, taking on the position of chairman until his retirement from Genentech in 1996. [5 ...
Pages in category "Drugs developed by Genentech" The following 102 pages are in this category, out of 102 total. This list may not reflect recent changes. A.
Genentech Announces FDA Approval of Tamiflu for the Treatment of Influenza in Infants -- First Medicine Approved to Treat Influenza in Infants Two Weeks of Age and Older -- SOUTH SAN FRANCISCO ...
From 2017 to 2018, he was the CEO of Genentech. [6] While at Genentech, he developed its immunology and ophthalmology divisions, managed the sales of Rituxan, Raptiva, and Xolair, and directed Roche's late-stage portfolio committee for nearly four years, where he was responsible for determining late-stage clinical trial advancements. [6]
MedImmune, Inc. v. Genentech, Inc., 549 U.S. 118 (2007), was a decision by the Supreme Court of the United States involving patent law. [1] It arose from a lawsuit filed by MedImmune which challenged one of the Cabilly patents issued to Genentech .